DiabetesInControl – New Long-acting Basal Insulin Shows Superiority in HbA1c Reduction

Last week, Eli Lilly and Company announced positive top-line results of three completed Phase III clinical trials in patients with type 2 diabetes for basal insulin peglispro (BIL), which is being studied as a once-daily treatment for both type 1 and type 2 diabetes.

Read more

Posted in Glucose & Insulin